Date Time
Update on DARE-19 Phase III trial for Farxiga in COVID-19
AstraZeneca and Saint Luke’s Mid America Heart Institute today announced high-level results of the primary analysis from the DARE-19 Phase III trial assessing the potential of Farxiga (dapagliflozin) to treat patients hospitalised with COVID-19 who are at risk of developing serious complications.
The trial did not achieve statistical significance for the primary endpoint of prevention measuring organ dysfunction and all-cause mortality, and the primary endpoint of recovery measuring a change in clinical status (from early recovery to death), at 30 days.
DARE-19 was the first Phase III trial to evaluate the safety and efficacy of a sodium-glucose co-transporter-2 (SGLT2) inhibitor in patients hospitalised with COVID-19 who also have risk factors for developing serious complications, including hypertension (HTN), type-2 diabetes (T2D), atherosclerotic cardiovascular disease (ASCVD), heart failure (HF) or chronic
Monday 12 April 2021 - 4:00pm
FILE: Several European countries have halted its use over fears the vaccine is causing blood clots.
AFP/Andrew Yates
AFP/Andrew Yates
LONDON - British pharmaceutical giant AstraZeneca on Monday said that following a trial, its diabetes drug Farxiga was not successful in treating COVID patients at risk of severe complications.
AstraZeneca, whose separate COVID-19 vaccine rollout has been hampered by health concerns, said its trial assessing the potential of Farxiga to treat patients hospitalised with COVID-19 who are at risk of developing serious complications. did not achieve statistical significance .
The trial was carried out alongside Saint Luke s Mid America Heart Institute and looked at potential complications including diabetes and heart failure.
AstraZeneca suffers diabetes drug setback for COVID AstraZeneca, whose separate COVID vaccine rollout has been hampered by health concerns, said its trial assessing the potential of Farxiga to treat patients hospitalised with COVID-19 who are at risk of developing serious complications. did not achieve statistical significance . FILE: Vials of the AstraZeneca COVID-19 vaccine and a syringe. Picture: Joel Saget/AFP.
4 hours ago
LONDON - British pharmaceutical giant AstraZeneca on Monday said that following a trial, its diabetes drug Farxiga was not successful in treating COVID patients at risk of severe complications.
AstraZeneca, whose separate COVID vaccine rollout has been hampered by health concerns, said its trial assessing the potential of Farxiga to treat patients hospitalised with COVID-19 who are at risk of developing serious complications. did not achieve statistical significance .
12 April 2021 | 07:49am
StockMarketWire.com - Pharmaceutical maker AstraZeneca and Saint Luke s Mid America Heart Institute said high-level results from a phase 3 trial assessing the potential of Farxiga to treat patients hospitalised with COVID-19 failed to meet its primary goal.
The trial failed to achieve statistical significance for the primary goal of prevention measuring organ dysfunction and all-cause mortality, and the primary endpoint of recovery measuring a change in clinical status (from early recovery to death), at 30 days, the company said.
The full trial results would be presented at the American College of Cardiology Scientific Sessions in May 2021. Story provided by StockMarketWire.com
9:51 a.m. ET, April 12, 2021
50% of US adults expected to have at least one dose of Covid-19 vaccine by end of this week
From CNN s Deidre McPhillips
People wait in line at a pop-up Coviid-19 vaccination site in Orlando, Florida, on April 9. Paul Hennessy/SOPA Images/LightRocket/Getty Images
If Covid-19 vaccinations continue at the current pace, the United States will likely hit a milestone this week: vaccinating half of adults with at least one dose of vaccine.
Over the past week, more than 3.1 million doses of vaccine have been administered each day on average, according to data reported by the US Centers for Disease Control and Prevention. Those doses could be first doses, second doses or single doses.